Kymera Therapeutics Inc (NAS:KYMR)
$ 50.94 1.09 (2.19%) Market Cap: 3.30 Bil Enterprise Value: 2.84 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 50/100

Q4 2023 Kymera Therapeutics Inc Earnings Call Transcript

Feb 22, 2024 / 01:30PM GMT
Release Date Price: $40.49 (+4.71%)
Operator

Good morning and welcome to the Kymera Therapeutics Fourth Quarter 2023 results call. (Operator Instructions) Please not this event is being recorded. I now turn the call over to Justine Koenigsberg.

Thank you.

Justine Koenigsberg
Kymera Therapeutics Inc - VP, IR

Good morning and welcome to Kymera's investor update. Joining me this morning are Nello Mainolfi, Founder, President and CEO; Jared Gollob, our Chief Medical Officer; and Bruce Jacobs, Chief Financial Officer. Following our prepared remarks, we will open the call to questions. We ask that you limit your questions to one and a relevant follow-up to allow enough time to address everyone's questions.

Before we begin, today's discussion will include forward-looking statements about our future expectations, plans and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10 K filed with the SEC. Any forward-looking statements speak only as of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot